Illumina Inc (ILMN)vsThermo Fisher Scientific Inc (TMO)
ILMN
Illumina Inc
$288.79
+3.33%
HEALTHCARE · Cap: $39.64B
TMO
Thermo Fisher Scientific Inc
$704.15
+0.71%
HEALTHCARE · Cap: $255.13B
Smart Verdict
WallStSmart Research — data-driven comparison
Thermo Fisher Scientific Inc generates 931% more annual revenue ($46.34B vs $4.49B). ILMN leads profitability with a 18.3% profit margin vs 15.0%. TMO appears more attractively valued with a PEG of 1.98. TMO earns a higher WallStSmart Score of 60/100 (C+).
ILMN
Buy51
out of 100
Grade: C-
TMO
Buy60
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+58.2%
Fair Value
$278.38
Current Price
$288.79
$10.41 discount
Intrinsic value data unavailable for TMO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 29 in profit
Strong operational efficiency at 21.1%
Mega-cap, among the largest globally
Generating 1.7B in free cash flow
Areas to Watch
Trading at 15.4x book value
Grey zone — moderate risk
Expensive relative to growth rate
Premium valuation, high expectations priced in
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ILMN
The strongest argument for ILMN centers on Return on Equity, Operating Margin. Profitability is solid with margins at 18.3% and operating margin at 21.1%.
Bull Case : TMO
The strongest argument for TMO centers on Market Cap, Free Cash Flow. Revenue growth of 10.5% demonstrates continued momentum.
Bear Case : ILMN
The primary concerns for ILMN are Price/Book, Altman Z-Score, PEG Ratio. A P/E of 49.0x leaves little room for execution misses.
Bear Case : TMO
The primary concerns for TMO are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
ILMN profiles as a mature stock while TMO is a value play — different risk/reward profiles.
ILMN carries more volatility with a beta of 1.42 — expect wider price swings.
TMO is growing revenue faster at 10.5% — sustainability is the question.
TMO generates stronger free cash flow (1.7B), providing more financial flexibility.
Bottom Line
TMO scores higher overall (60/100 vs 51/100) and 10.5% revenue growth. ILMN offers better value entry with a 58.2% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Illumina Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Illumina, Inc. is an American company. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets. Its headquarters are located in San Diego, California.
Visit Website →Thermo Fisher Scientific Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific, to form a company with US$ 9 billion in combined revenues.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?